今天是第19个国际罕见病日。罕见病，又称"孤儿病"，对患者家庭而言，误诊、药少、费用高曾是他们的常见困境。但这些年，我国罕见病诊疗 事业进步显著，正在不断打破"罕见"壁垒，让罕见病逐渐被看见，让罕见病诊疗不再罕见。 截至目前，我国罕见病诊疗协作网覆盖419家医院，罕见病目录、医保用药持续扩容，多学科会诊、AI辅助诊断让诊疗更可及，为更多患者家庭 带去希望。那么未来如何更进一步完善罕见病诊疗体系，持续点亮每一个小群体的生命之光？ 2月26日，北京协和医院疑难罕见病会诊中心，一场多学科会诊正在进行，多个科室的专家共同为一名患有两种遗传性罕见病的年轻女性患者进行 远程问诊、分析病情、制定诊疗方案。 北京协和医院肾内科主任陈丽萌介绍，此前这名患者多次发生严重的过敏反应、消化道出血，在治疗一段时间后，患者已经回到了工作岗位。这 次会诊，他们除了要了解患者近期情况，还要探讨后续疾病治疗的方案。 近年来，多部门持续求解罕见病诊疗的难题。我国将罕见病防治纳入《"健康中国2030"规划纲要》。 在临床研究领域，现行罕见病病种诊疗指南针对86种罕见病给出全流程诊疗指导，涵盖诊断方法、治疗方案、康复建议等内容。北京协和医院院 长张 ...

Core Viewpoint - The implementation of a unified medical service pricing mechanism in Gansu aims to address the long-standing issues of inconsistent pricing and project naming in healthcare services, enhancing the management of nearly 3,000 medical service price items across the province [1][2]. Group 1: Focus on Children - New nursing guidelines include pricing for "premature infant care" and "newborn care," which will be incorporated into the medical insurance payment system, reimbursed at the standard for Class A projects [2]. - Additional pricing items for children under six years old have been established to incentivize healthcare providers to offer higher quality services to young patients [2]. - The pricing mechanism acknowledges the value of nursing staff's expertise and labor in high-risk premature infant care, reflecting respect for medical professionals [2]. Group 2: Focus on the Elderly - The implementation of the pricing guidelines has significantly improved services for the elderly, introducing fees for home hospital beds, home care services, and palliative care [2]. - These new medical service price items allow elderly individuals with mobility issues to receive professional medical care at home, particularly during end-of-life stages, ensuring comprehensive physical and psychological support [2]. Group 3: Support for Innovation - Adjustments in medical service pricing have facilitated the clinical application of advanced technologies such as invasive brain-machine interface technology and AI-assisted diagnostics [2]. - The introduction of air medical transport projects will enhance the emergency rescue capabilities of hospitals, creating an efficient "air life channel" for the public [2]. Group 4: Overall Impact - The Gansu Provincial Medical Insurance Bureau aims to standardize hospital charges through these pricing adjustments, making healthcare access more convenient and strengthening medical security, ultimately improving the health satisfaction of the populace [3].

方案要求，探索开展市域疾控联合体建设。医疗机构要加强公共卫生科、职业病防治科或预防保健 科等直接从事疾控工作的科室建设，依法落实传染病疫情和突发公共卫生事件报告、哨点监测、职业健 康检查、职业病及疑似职业病报告、诊疗管理、健康教育、预防接种和行为干预等职责。乡镇卫生院和 社区卫生服务中心至少配备1名公共卫生医师，具备监测、筛查、隔离观察、转诊和随访管理能力，开 展预防接种服务。 编辑：霍悦 此外，方案提出，加强基层"数智疾控"建设，全面开展电子预防接种证建设和应用，到2026年，基 本实现预防接种信息跨地区互联互通。探索在基层医疗卫生机构运用远程医疗、人工智能辅助诊断等技 术，提高结核病、地方病及慢性病等诊断效率和质量。 新华社北京1月27日电（记者徐鹏航）国家疾控局等部门27日公开发布《疾病预防控制领域强基实 施方案》，明确到2027年底，基层疾控工作网络基本健全，构建起现代化疾控体系的基础框架。到2030 年，基层疾控体系功能持续优化，运行更加高效。 在强化基层防治队伍建设方面，方案明确，原则上，市级传染病应急小分队不少于10人、流行病学 调查专家队不少于15人，常备流行病学调查员的数量占本单位在职人员数 ...

今天，记者在湖南省县级公立医院眼科能力提升建设项目2025年度总结会上获悉，2021年10月至今，通 过该项目的落地，96家医院开展新技术，独立眼科由原来的3家增加到21家，14家医院设置眼科（含在 五官科内），63家医院新增眼底相机，我省基层眼科服务能力明显提升。 "针对前期调研发现我省基层医疗机构眼科缺人、缺设备、缺眼底病诊疗能力，导致很多老百姓在当地 无法得到及时诊治的情况，我们改变传统帮扶模式，通过AI赋能，利用项目经费为基层医疗机构提供 眼底相机，建立一分钟快速识别眼底病变和全身慢病的预警机制，在保障医疗服务水平的同时极大解决 了基层眼科医生匮乏和能力不足的问题。"湘雅二医院项目负责人罗静教授介绍，项目已累计完成AI辅 助阅片和远程会诊4万余人次，指导基层开展眼科手术300余台，使群众在县域内即可获得专家级诊疗方 案。我省"人工智能辅助诊断系统在基层致盲性眼病筛查中的作用"入选国家卫生健康委适宜技术推广备 选库。 会上 ，来自桃源县中医医院、石门县人民医院、祁阳市人民医院、湘乡市人民医院、慈利县中医医 院、新宁县人民医院、宁乡市中医医院、隆回县人民医院等优秀项目单位代表，围绕学科建设路径、人 才梯队 ...

Market Overview - The A-share market is showing strong performance, with the Shanghai Composite Index surpassing 4100 points and trading volume exceeding 3 trillion [1] - The Hong Kong market is lagging, influenced by overseas events, particularly geopolitical tensions involving Iran and Mexico [1] - The U.S. Supreme Court's delay in ruling on tariffs is seen as a positive development for the market [1] Industry Insights - The commercial aerospace sector is highlighted as a strong investment theme, with China submitting applications for an additional 203,000 satellites, covering 14 satellite constellations [1] - The U.S. FCC has approved SpaceX's deployment of 7,500 second-generation satellites, indicating a competitive landscape in satellite technology [1] Company Developments - SanDisk has introduced a novel contract requiring full cash prepayment from clients to secure supply quotas for 1 to 3 years, benefiting the related supply chain [2] - New Sword Transmission, a key supplier for Tesla's humanoid robot, has initiated its IPO process, marking a significant milestone in the mass production of humanoid robots [2] Financial Highlights - WuXi Biologics reported a record high of 209 new projects signed in 2025, with a significant portion coming from the U.S. market [3] - The company has 945 ongoing projects, including 74 in Phase III clinical trials, which are expected to drive future revenue growth [3] - WuXi Biologics anticipates a 120%+ year-on-year revenue growth in 2025, with a total potential milestone payment of over $4 billion from collaborative projects [3] Technological Advancements - OpenAI has launched ChatGPT Health, integrating user medical records and health data to assist in understanding health reports and preparing for medical consultations [4] - The AI-assisted diagnostic services have been included in China's medical insurance framework, paving the way for more companies to apply for relevant certifications [5]

Investment Rating - The report assigns an "Overweight" rating for the healthcare service industry [3]. Core Insights - The healthcare insurance fund's income showed stable growth in 2025, with a cumulative income of CNY 26,320.68 billion from January to November, reflecting a year-on-year increase of 2.9%. The income from urban employee insurance reached CNY 16,643.79 billion (+5.7%), while the income from rural resident insurance decreased by 1.6% to CNY 9,676.89 billion [2][4]. - The cumulative expenditure of the healthcare insurance fund from January to November was CNY 21,100.46 billion, marking a year-on-year increase of 0.5%. Urban employee insurance expenditure was CNY 12,033.33 billion (+2.4%), and rural resident insurance expenditure was CNY 9,067.14 billion (-1.9%) [4][9]. - The cumulative surplus of the healthcare insurance fund as of November 2025 was CNY 5,220.22 billion, with a surplus rate of 19.8%. The urban employee insurance fund had a surplus of CNY 4,610.46 billion (27.7%), while the rural resident insurance fund had a surplus of CNY 609.75 billion (6.3%) [4][9]. Summary by Sections Income and Expenditure - The healthcare insurance fund's income in November 2025 was CNY 2,800.58 billion, showing a month-on-month increase of 11.2%. The urban employee insurance fund's income was CNY 1,492.65 billion (+4.4%), and the rural resident insurance fund's income was CNY 1,307.92 billion (+20.1%) [9]. - The expenditure for November 2025 was CNY 2,064.22 billion, reflecting a year-on-year increase of 13.0%. Urban employee insurance expenditure was CNY 1,093.39 billion (+3.9%), and rural resident insurance expenditure was CNY 970.85 billion (+25.3%) [9]. Fiscal Health Expenditure - Cumulative health expenditure from the general public budget was CNY 18,687 billion from January to November 2025, with a year-on-year growth of 4.7%. The expenditure in November alone was CNY 1,810 billion, marking a significant increase of 32.5% [7][8].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of December 28, 2025 [1] Core Insights - The report highlights the intensive policy support for brain-computer interface (BCI) technology development, particularly in the medical field, with several policies already implemented [2] - It emphasizes the significant market opportunity in radiation therapy equipment, particularly the ZAP-X system, which is expected to capture a substantial share of the growing market for non-invasive tumor radiation treatment [3] - The introduction of pathology fee reforms is seen as a breakthrough for the commercialization of AI applications in pathology, allowing for better integration of AI-assisted diagnostics into the pricing structure [5] - The report discusses the trend of Chinese innovative drugs entering international markets, which is expected to reduce domestic competition and provide new valuation anchors for these companies [6] - It also notes the promising developments in oral autoimmune drugs and small nucleic acid drugs, with several companies making significant progress in clinical trials [7][9] Summary by Sections 1. Policy Support for BCI Technology - In July 2025, a joint opinion was issued by multiple government departments to promote BCI industry innovation, with medical health being a core application area [2] - The National Medical Products Administration (NMPA) has prioritized the approval of implantable BCI medical devices, with expected registration certificates to be issued by Q1 2026 [2] 2. Radiation Therapy Equipment Market - The ZAP-X system is designed for precise radiation therapy for brain tumors, with a significant patient population in China, estimated at 1.5 million new cases of brain metastases annually [3] - The non-invasive tumor radiation treatment market is projected to grow from RMB 27.2 billion in 2018 to RMB 59.4 billion by 2024, with a compound annual growth rate (CAGR) of 13.9% [3] 3. AI in Pathology - The NMPA's new guidelines for pathology services include AI-assisted diagnostics as an expansion item, which will help streamline the commercialization of AI technologies in pathology [5] 4. Innovative Drug Exports - The report notes that partnerships between Chinese companies and international firms are increasing, providing funding and reducing competition in the domestic market [6] - The innovative drug index has risen by 38.11% since the beginning of 2025, outperforming the CSI 300 index [6] 5. Oral Autoimmune Drugs - Takeda's new oral TYK2 inhibitor has shown positive results in clinical trials for psoriasis, indicating a potential breakthrough in treatment options [7] - Several domestic companies are also advancing in the development of oral autoimmune drugs targeting various conditions [7] 6. Small Nucleic Acid Drugs - Yuyuan Pharmaceutical's YKYY032 injection has received clinical approval from both the FDA and NMPA, with multiple companies in China advancing in the small nucleic acid drug space [9] - The report highlights the reliability of domestic technology platforms as they progress through clinical trials [9] 7. Stock Recommendations - The report recommends specific companies based on the identified opportunities, including Meihua Medical for BCI technology, Baiyang Pharmaceutical for ZAP-X, and Yuyuan Pharmaceutical for small nucleic acid drugs [11]

Group 1: Zhongsheng Pharma - The core business of Zhongsheng Pharma has stabilized after experiencing centralized procurement, with innovative drug research and development gradually yielding results, particularly in respiratory and metabolic fields [2][4] - The company reported a revenue of 1.889 billion yuan for the first three quarters of 2025, a year-on-year decrease of 1.01%, while net profit attributable to shareholders increased by 68.40% to 251 million yuan [4] - The core products of traditional Chinese medicine have maintained stable growth post-collective procurement, with sales resilience supported by volume compensating for price reductions [4][5] - The innovative pipeline includes RAY1225 injection, a dual-target drug for weight loss and blood sugar reduction, which has shown positive results in clinical trials [5] Group 2: Medical Device Industry - The brain-computer interface (BCI) industry in China has achieved rapid development under policy support, with a focus on establishing a robust technological and industrial framework by 2027 [6][8] - The National Medical Products Administration held a meeting to discuss the advancement of BCI medical devices, emphasizing safety and effectiveness as primary considerations [17] - By 2030, the BCI industry aims to cultivate globally influential leading enterprises and a competitive industrial ecosystem, with significant advancements expected in technology and application [18]

Core Viewpoint - The article discusses the recent advancements and strategic importance of brain-computer interface (BCI) medical devices, highlighting the government's commitment to fostering innovation and establishing a robust industry framework by 2030 [3][4]. Group 1: Policy and Strategic Importance - The National Medical Products Administration held a meeting on December 18, 2025, to discuss the development of BCI medical devices, emphasizing the need for safety and effectiveness as primary considerations [3]. - The meeting called for enhanced collaboration across various sectors, including academia, research, and medical institutions, to address key technical challenges and improve the supply chain [3]. - The Ministry of Industry and Information Technology, along with six other departments, previously issued guidelines to promote innovation in the BCI industry, recognizing it as a frontier technology merging life sciences and information sciences [3]. Group 2: Industry Development Goals - By 2027, significant breakthroughs in BCI technology are expected, with the establishment of advanced technical, industrial, and standard systems, aiming for products to reach international standards in performance [4]. - The BCI industry is projected to expand significantly, creating 2 to 3 industrial clusters and exploring new applications and business models by 2027 [4]. - By 2030, the BCI industry aims to enhance its innovation capabilities, develop a reliable industrial ecosystem, and nurture 2 to 3 globally influential leading companies alongside a number of specialized small and medium enterprises [4].

Investment Rating - The report assigns an "Accumulate" rating to the medical device industry, indicating a positive outlook for investment opportunities [4]. Core Insights - The National Healthcare Security Administration (NHSA) issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)," which is expected to standardize the artificial intelligence-assisted diagnosis market [2][4]. - The guidelines consolidate existing pricing projects into 28 items, with 3 additional charges and 2 expansion items, aiming to create a unified pricing standard across provinces [4]. - The inclusion of "AI-assisted diagnosis" as an expansion item in the pricing guidelines is anticipated to regulate the market and stimulate research and development in the industry [4]. Summary by Sections - **Policy Implementation**: The NHSA's guidelines are part of a broader initiative to reform medical service pricing, promoting a structured approach to pricing in pathology services [4]. - **Pricing Structure**: The guidelines specify that the pricing for pathology diagnosis includes costs associated with sample reception, interpretation, diagnosis, AI assistance, and report generation [4]. - **Digital Transformation**: The requirement for medical institutions to upload pathology reports and digital images is expected to drive the adoption of digital technologies and facilitate nationwide sharing of diagnostic results [4].